<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834440</url>
  </required_header>
  <id_info>
    <org_study_id>MF2467-2021-14</org_study_id>
    <nct_id>NCT04834440</nct_id>
  </id_info>
  <brief_title>Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)</brief_title>
  <official_title>Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the minimal effective ropivacaine concentration&#xD;
      required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Before induction of GA, all patients will receive sciatic, obturator, lateral femoral&#xD;
           cutaneous and femoral nerve blocks.&#xD;
&#xD;
        -  The femoral nerve block will be performed using 15ml of ropivacaine which concentration&#xD;
           relied on the response of the previous patient.&#xD;
&#xD;
        -  Based on biased-coin design up-down sequential method: when a patient has a negative&#xD;
           response, the next patient will receive a concentration 0.01% w/v higher. However if he&#xD;
           has a positive response, the next patient will be randomized to receive either the same&#xD;
           ropivacaine concentration or a concentration 0.01% w/v less.&#xD;
&#xD;
        -  Patients with pain free recovery will be considered to have positive response.&#xD;
&#xD;
        -  Patients' responses will be analyzed to calculate the MEAC90&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effective analgesic femoral nerve block</measure>
    <time_frame>in recovery unit (one hour after surgery)</time_frame>
    <description>postoperative pain. it will be assessed using numerical rating scale (NRS). NRS, 0 = no pain; 10 = worst pain imaginable; if NRS â‰¥ 3, pain (ineffective block) is considered, other wise a successful block will be considered.</description>
  </primary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Postoperative Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>all patients will receive femoral nerve block using same volume of ropivacaine but in different concentrations</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, who are scheduled for knee ligament reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 y,&#xD;
&#xD;
          -  ASA physical class greater &gt;III&#xD;
&#xD;
               -  BMI &gt;40 has any contraindication for medications or techniques used in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Healthpoint Hospital</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>112308</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healthpoint Hospital</investigator_affiliation>
    <investigator_full_name>Ahmad Muhammad Taha</investigator_full_name>
    <investigator_title>Consultant of anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

